Curia Global, commonly referred to as Curia, is a leading contract research, development, and manufacturing organisation headquartered in the United States. Established in 2019, Curia has rapidly expanded its operational footprint across North America and Europe, positioning itself as a key player in the pharmaceutical and biotechnology sectors.
Specialising in drug development and manufacturing, Curia offers a comprehensive suite of services, including analytical testing, formulation development, and commercial manufacturing. What sets Curia apart is its commitment to quality and innovation, ensuring that clients receive tailored solutions that meet stringent regulatory standards.
With a strong market presence, Curia has achieved significant milestones, including strategic acquisitions that enhance its capabilities. The company is recognised for its expertise in complex drug modalities, making it a trusted partner for clients seeking to navigate the complexities of drug development.
-8 vs industry average
Curia’s score of 30 is higher than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Curia?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2024
Reported emissions
Scope 3 accounts for ••• of total emissions.
Curia's reported carbon emissions
In 2021, Curia Global, Inc. reported total carbon emissions of approximately 87,199,130 kg CO2e, comprising 41,290,410 kg CO2e from Scope 1 and 46,508,720 kg CO2e from Scope 2 emissions. Notably, the company has not disclosed any Scope 3 emissions data. Curia is committed to achieving net-zero emissions across all scopes by 2050, with interim targets set through the Science Based Targets initiative (SBTi). The company is actively working towards these long-term climate commitments, reflecting its dedication to sustainability within the pharmaceuticals, biotechnology, and life sciences sector. As part of its climate strategy, Curia is focused on reducing its carbon footprint and enhancing its environmental performance, aligning with industry standards and best practices.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Curia’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Curia yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Curia
Frequently asked questions
Common questions about Curia’s sustainability data and climate commitments
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project